Silesian Centre for Heart Diseases, Medical University of Silesia, Zabrze, Poland.
Int J Cardiol. 2013 Sep 20;168(1):250-4. doi: 10.1016/j.ijcard.2012.09.086. Epub 2012 Oct 8.
Three-vessel coronary artery disease is associated with high mortality in patients with non-ST-segment elevation myocardial infarction (NSTEMI). The purpose of this study was to assess the impact on 12-month mortality of chronic total occlusion (CTO) in the non-infarct-related artery (non-IRA), as assessed by coronary angiography during percutaneous coronary intervention (PCI) for NSTEMI, of patients with 3-vessel disease.
The study included all of the NSTEMI patients with 3-vessel disease by coronary angiogram who were treated by PCI and who were registered in the prospective Polish Registry of Acute Coronary Syndromes (PL-ACS) from July 2007 to November 2009. The patients with prior coronary artery bypass grafting and those with significant stenosis of the left main coronary artery were excluded. The 12-month mortality was obtained from a government database.
Of the 925 patients fulfilling the inclusion and exclusion criteria, 438 (47.4%) patients had 1 or more CTO of a major non-IRA coronary artery (+CTO), and 487 (52.6%) patients had 3-vessel disease without CTO (-CTO). The in-hospital mortality for the +CTO and -CTO patients was 5.3% and 2.1%, respectively (p=0.009), whilst the 12-month mortality was 21.1% and 11.9%, respectively (p=0.0001). After multivariate adjustment for differences in the baseline characteristics, the presence of CTO remained significantly associated with higher 12-month mortality (relative risk=1.42, 95%CI=1.01-2.00, p=0.047).
The presence of CTO in non-IRA in patients with NSTEMI and 3-vessel coronary disease predicts higher 12-month mortality.
三支血管冠状动脉疾病与非 ST 段抬高型心肌梗死(NSTEMI)患者的高死亡率相关。本研究旨在评估经皮冠状动脉介入治疗(PCI)期间冠状动脉造影评估的非梗死相关动脉(非 IRA)慢性完全闭塞(CTO)对 3 血管病变的 NSTEMI 患者 12 个月死亡率的影响。
该研究纳入了 2007 年 7 月至 2009 年 11 月期间经冠状动脉造影诊断为 3 血管病变并接受 PCI 治疗的所有 NSTEMI 患者,并在前瞻性波兰急性冠状动脉综合征登记处(PL-ACS)进行登记。排除了既往冠状动脉旁路移植术患者和左主干冠状动脉有显著狭窄的患者。12 个月死亡率来自政府数据库。
在符合纳入和排除标准的 925 名患者中,438 名(47.4%)患者有 1 条或多条主要非 IRA 冠状动脉 CTO(+CTO),487 名(52.6%)患者无 CTO(-CTO)。+CTO 和-CTO 患者的院内死亡率分别为 5.3%和 2.1%(p=0.009),而 12 个月死亡率分别为 21.1%和 11.9%(p=0.0001)。在对基线特征差异进行多变量调整后,CTO 的存在与较高的 12 个月死亡率显著相关(相对风险=1.42,95%CI=1.01-2.00,p=0.047)。
NSTEMI 和 3 血管病变患者非 IRA 中的 CTO 存在预示着较高的 12 个月死亡率。